An Observational Study Evaluating Efficacy, Safety and Convenience of NovoNorm® in Treatment of Type 2 Diabetes in Routine Clinical Practice

Novo Nordisk A/S30,554 enrolled

Overview

This study is conducted in Africa and Asia. The aim of this study is to evaluate the efficacy, safety and convenience of using repaglinide (NovoNorm®) in type 2 diabetes management in routine clinical practice.

Study Type

OBSERVATIONAL

Enrollment

30,554

Conditions

Diabetes Diabetes Mellitus, Type 2

Interventions

repaglinideDRUG

Prescription according to the product labelling at the physicians' discretion

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Type 2 diabetes * Newly diagnosed or not adequately controlled with current therapy

Locations (1)

Novo Nordisk Investigational Site

Istanbul, Turkey (Türkiye)

Outcomes

Primary Outcomes

HbA1c (glycosylated haemoglobin)

Secondary Outcomes

Fasting Plasma Glucose (FPG)

Postprandial glucose values

Incidence of hypoglycaemia

Adverse drug reactions (ADR)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.